


CLAIMS:

1. A compound of formula **Ia**, or a pharmaceutically acceptable salt or solvate thereof:



5 wherein:

R₁ is hydrogen, C₁-C₆ alkyl, partially or fully deuterated C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₂-C₆ cyanoalkyl, C₁-C₆ mercaptoalkyl or amino;


R₄ is hydrogen or C₁-C₃ alkyl;

R₅ is hydrogen or C₁-C₂ alkyl;

- 10 or **R₄** and **R₅** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the **CH₂** moiety is optionally substituted with two deuterium atoms;

R₆ is C₁-C₆ alkyl or partially or fully deuterated C₁-C₆ alkyl;

A is C₅-C₇ cycloalkyl, furanyl, thiophenyl, methylthiophenyl or



15 wherein:

X₁ is hydrogen, halo or methyl;

X₁' is hydrogen or halo;

X₂ is hydrogen, halo or methyl;

- 20 **X₂'** is hydrogen or halo;

X₃ is hydrogen or fluoro;


n is 0 or 1, and when **n** is 0 a single bond joins the carbon atoms to which the **CH₂** moiety would be attached when **n** is 1.

- 25 2. A compound according to claim 1, wherein **n** is 0.


3. A compound according to claims 1 or 2, wherein **R₄** and **R₅** combine, together with the carbon atom to which they are attached, to form a cyclopropyl ring wherein the **CH₂** moiety is optionally substituted with two deuterium atoms.

5


4. A compound according to claims 1 to 3, wherein more than 50% of substituents **R₅** and **A** have the stereochemical configuration of formula **Id**



10 5. A compound according to claims 1 to 3, wherein more than 50% of substituents **R₅** and **A** have the stereochemical configuration of formula **Ie**



6. A compound according to claims 1 to 5, wherein **A** is



15

wherein **X₁**, **X₁'**, **X₂**, **X₂'** and **X₃** are as defined in claim 1.

7. A compound according to claims 1 to 6, wherein **R₁** is hydrogen, methyl, *d*3-methyl, propyl, cyclopropyl, cyanomethyl, mercaptoethyl or amino.

20


8. A compound according to claims 1 to 2 or 4 to 7, wherein **R₄** is hydrogen or methyl.

9. A compound according to claims 1 to 2 or 4 to 8, wherein **R₅** is hydrogen or methyl.

10. A compound according to claims 1 to 9, wherein **R₆** is methyl, n-butyl or *d*₃-methyl;

5

11. A compound according to claims 1 to 10, wherein **A** is



wherein:

X₁ is hydrogen, fluoro, chloro or methyl;

10 **X₁'** is hydrogen, fluoro or chloro;

X₂ is hydrogen, fluoro, chloro, bromo or methyl;

X₂' is hydrogen, fluoro, chloro or bromo;

X₃ is hydrogen or fluoro.

15 12. A compound of formula **Ia**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.





13. A compound of formula **Ia**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of conditions ameliorated by inhibition of
20 dopamine-beta-hydroxylase.


14. Use of a compound of formula **Ia**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treatment of conditions ameliorated by inhibition of dopamine-beta-hydroxylase.

25


15. A pharmaceutical composition comprising (i) a therapeutically effective amount of a compound of formula **Ia**, as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof; and (ii) a pharmaceutically acceptable excipient.

16. A compound according to claim 1, wherein the compound is selected from the group consisting of:







,




,








,








,







,





5



5 or a pharmaceutically acceptable salt or solvate thereof.